STOCK TITAN
  1. Home
  2. Sec-filings
  3. MNPR
  4. [Form 4] Monopar Therapeutics Insider Trading Activity

Monopar Therapeutics (MNPR) director sells 4,090 shares near $110

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Monopar Therapeutics (MNPR) director Tsuchimoto Kim R reported multiple open-market sales of common stock. On August 26, 2026, the reporting person sold a total of 4,090 shares of Monopar common stock in six transactions, each reported at a weighted average price between $108.83 and $113.84 per share. The trades were effected pursuant to a Rule 10b5-1 Plan executed on May 27, 2026, and each sale was executed through multiple trades within disclosed price ranges.

Positive

  • None.

Negative

  • None.
Insider Tsuchimoto Kim R
Role Director
Sold 4,090 shs ($456K)
Type Security Shares Price Value
Sale Common Stock F1, F2 485 $108.83 $53K
Sale Common Stock F1, F3 615 $109.56 $67K
Sale Common Stock F1, F4 700 $110.65 $77K
Sale Common Stock F1, F5 1,098 $111.84 $123K
Sale Common Stock F1, F6 602 $112.93 $68K
Sale Common Stock F1, F7 590 $113.84 $67K
Holdings After Transaction: Common Stock — 7,396 shares (Direct)
Footnotes (7)
  1. F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
  6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
  7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
Total shares sold 4,090 shares of Common Stock Aggregate of six open-market sale transactions on August 26, 2026
Shares sold at $108.83 485 shares at $108.83 per share Weighted average price; trades within $108.07–$109.05 range
Shares sold at $109.56 615 shares at $109.56 per share Weighted average price; trades within $109.07–$110.04 range
Shares sold at $110.65 700 shares at $110.65 per share Weighted average price; trades within $110.14–$111.05 range
Shares sold at $111.84 1,098 shares at $111.84 per share Weighted average price; trades within $111.30–$112.27 range
Shares sold at $112.93 602 shares at $112.93 per share Weighted average price; trades within $112.30–$113.25 range
Shares sold at $113.84 590 shares at $113.84 per share Weighted average price; trades within $113.35–$114.34 range
Rule 10b5-1 Plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 Plan executed"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open market or private transaction financial
"Sale in open market or private transaction"

FAQ

What insider transaction did MNPR director Tsuchimoto Kim R report?
Tsuschimoto Kim R reported selling 4,090 shares of Monopar Therapeutics common stock on August 26, 2026, in six separate open-market transactions, all under a Rule 10b5-1 trading plan executed on May 27, 2026.

At what prices were the MNPR shares sold in this Form 4 filing?
The six reported sales used weighted average prices ranging from $108.83 to $113.84 per share. Footnotes state that the underlying trades occurred within price ranges from $108.07–$114.34, inclusive, for the respective transaction blocks.

How many MNPR shares were sold in each reported transaction block?
The reported blocks were 485 shares at $108.83, 615 at $109.56, 700 at $110.65, 1,098 at $111.84, 602 at $112.93, and 590 at $113.84, all common stock sales on August 26, 2026.

Was the MNPR insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026, and the Rule 10b5-1 checkbox for the filing is affirmed.

Does the Form 4 disclose price ranges for the MNPR share sales?
Yes. Footnotes disclose that each weighted average price reflects multiple trades within ranges including $108.07–$109.05, $109.07–$110.04, $110.14–$111.05, $111.30–$112.27, $112.30–$113.25, and $113.35–$114.34 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tsuchimoto Kim R
(Last)(First)(Middle)
1000 SKOKIE BLVD SUITE 350
(Street)
WILMETTE ILLINOIS 60091
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/26/2026S(1)485D$108.83(2)11,001D
Common Stock08/26/2026S(1)615D$109.56(3)10,386D
Common Stock08/26/2026S(1)700D$110.65(4)9,686D
Common Stock08/26/2026S(1)1,098D$111.84(5)8,588D
Common Stock08/26/2026S(1)602D$112.93(6)7,986D
Common Stock08/26/2026S(1)590D$113.84(7)7,396D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
/s/ Quan Vu, Attorney-in-fact08/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR